Sign In
Buy TGTX
TG Therapeutics Earnings Calls
| Release date | Nov 03, 2025 |
| EPS estimate | $0.240 |
| EPS actual | $2.43 |
| EPS Surprise | 912.50% |
| Revenue estimate | 181.392M |
| Revenue actual | 161.709M |
| Revenue Surprise | -10.85% |
| Release date | Aug 04, 2025 |
| EPS estimate | $0.320 |
| EPS actual | $0.170 |
| EPS Surprise | -46.88% |
| Revenue estimate | 146.274M |
| Revenue actual | 141.148M |
| Revenue Surprise | -3.50% |
| Release date | May 05, 2025 |
| EPS estimate | $0.180 |
| EPS actual | $0.0300 |
| EPS Surprise | -83.33% |
| Revenue estimate | 134.2M |
| Revenue actual | 120.856M |
| Revenue Surprise | -9.94% |
| Release date | Mar 03, 2025 |
| EPS estimate | $0.0800 |
| EPS actual | $0.150 |
| EPS Surprise | 87.50% |
| Revenue estimate | 108.8M |
| Revenue actual | 108.185M |
| Revenue Surprise | -0.565% |
Last 4 Quarters for TG Therapeutics
Below you can see how TGTX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 03, 2025 |
| Price on release | $34.42 |
| EPS estimate | $0.0800 |
| EPS actual | $0.150 |
| EPS surprise | 87.50% |
| Date | Price |
|---|---|
| Feb 25, 2025 | $29.21 |
| Feb 26, 2025 | $29.34 |
| Feb 27, 2025 | $28.53 |
| Feb 28, 2025 | $30.09 |
| Mar 03, 2025 | $34.42 |
| Mar 04, 2025 | $35.62 |
| Mar 05, 2025 | $35.11 |
| Mar 06, 2025 | $35.19 |
| Mar 07, 2025 | $38.44 |
| 4 days before | 17.84% |
| 4 days after | 11.68% |
| On release day | 3.49% |
| Change in period | 31.60% |
| Release date | May 05, 2025 |
| Price on release | $37.68 |
| EPS estimate | $0.180 |
| EPS actual | $0.0300 |
| EPS surprise | -83.33% |
| Date | Price |
|---|---|
| Apr 29, 2025 | $43.86 |
| Apr 30, 2025 | $45.51 |
| May 01, 2025 | $45.37 |
| May 02, 2025 | $43.44 |
| May 05, 2025 | $37.68 |
| May 06, 2025 | $34.86 |
| May 07, 2025 | $34.85 |
| May 08, 2025 | $33.86 |
| May 09, 2025 | $33.64 |
| 4 days before | -14.09% |
| 4 days after | -10.72% |
| On release day | -7.48% |
| Change in period | -23.30% |
| Release date | Aug 04, 2025 |
| Price on release | $28.72 |
| EPS estimate | $0.320 |
| EPS actual | $0.170 |
| EPS surprise | -46.88% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $35.33 |
| Jul 30, 2025 | $36.27 |
| Jul 31, 2025 | $35.50 |
| Aug 01, 2025 | $35.02 |
| Aug 04, 2025 | $28.72 |
| Aug 05, 2025 | $28.40 |
| Aug 06, 2025 | $27.70 |
| Aug 07, 2025 | $27.89 |
| Aug 08, 2025 | $26.71 |
| 4 days before | -18.71% |
| 4 days after | -7.00% |
| On release day | -1.11% |
| Change in period | -24.40% |
| Release date | Nov 03, 2025 |
| Price on release | $33.69 |
| EPS estimate | $0.240 |
| EPS actual | $2.43 |
| EPS surprise | 912.50% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $34.55 |
| Oct 29, 2025 | $33.78 |
| Oct 30, 2025 | $34.02 |
| Oct 31, 2025 | $34.78 |
| Nov 03, 2025 | $33.69 |
| Nov 04, 2025 | $33.81 |
| Nov 05, 2025 | $34.04 |
| Nov 06, 2025 | $33.26 |
| Nov 07, 2025 | $32.24 |
| 4 days before | -2.49% |
| 4 days after | -4.30% |
| On release day | 0.356% |
| Change in period | -6.69% |
TG Therapeutics Earnings Call Transcript Summary of Q3 2025
TG Therapeutics reported a strong Q3 2025 driven by BRIUMVI sales and continued operational execution. Key financials: total revenue $161.7M (+93% YoY), U.S. BRIUMVI net sales ~$152.9M in Q3, updated full-year 2025 BRIUMVI net revenue guidance to ~$575–585M, GAAP net income of $390.9M ($2.43/sh) reflecting a nonrecurring $365M tax benefit from releasing a deferred tax asset valuation allowance, ~ $178M cash & investments at quarter-end, and full-year OpEx guidance of ~$300–320M. Commercially, BRIUMVI showed strong demand, high persistence, expanding prescriber base, and positive real-world / long-term data (6-year OLE data cited). Two pivotal lifecycle programs are underway: ENHANCE (consolidated day 1 dosing; enrollment complete; data mid-2026; potential launch 2027) and a Phase III subcutaneous ublituximab program (self-administered formulation; enrollment on track; pivotal data late-2026/early-2027; potential approval/launch 2028). Management views the subcutaneous program as materially expanding the TAM for their CD20 franchise. TG completed an initial $100M share repurchase and received board approval for an additional $100M program. Management emphasized disciplined capital deployment, continued R&D investment (including azer-cel allogeneic CAR-T for progressive MS), and expects continued profitability barring any one-time BD transactions. Risks noted include typical forward-looking uncertainties and that the tax benefit is non-cash and one-time.
